Hengrui Pharmaceutical announced that some products are included in the “National Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance” and will be implemented from January 1, 2026. Among them, 10 drugs, including injectable Recon trastuzumab, were introduced for the first time; 3 new indications were included for injectable carelizumab; 5 drugs, including pyrrolitinib maleate tablets, were successfully renewed; and 2 drugs, including apatinib mesylate tablets, were added and adjusted to routine catalogue management. The total sales volume of these drugs in 2024 was about 8.66 billion yuan, and about 7.554 billion yuan in the 1st to 3rd quarter of 2025. The impact on the company's performance cannot yet be estimated.

Hengrui Pharmaceutical announced that some products are included in the “National Catalogue of Drugs for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance” and will be implemented from January 1, 2026. Among them, 10 drugs, including injectable Recon trastuzumab, were introduced for the first time; 3 new indications were included for injectable carelizumab; 5 drugs, including pyrrolitinib maleate tablets, were successfully renewed; and 2 drugs, including apatinib mesylate tablets, were added and adjusted to routine catalogue management. The total sales volume of these drugs in 2024 was about 8.66 billion yuan, and about 7.554 billion yuan in the 1st to 3rd quarter of 2025. The impact on the company's performance cannot yet be estimated.